Table 2. The DOAC Score.

Presented is the final clinical risk prediction scoring system, termed the DOAC Score. Point assignments are based on patient characteristics. The prediction score was developed in the RE-LY trial among participants taking dabigatran 150 mg twice a day and then refined among individuals in the GARFIELD-AF registry among participants on all DOACs. Point assignments were based on the coefficients of these variables in a Cox regression model (presented in the Supplement) for the outcome of major bleeding. The maximum number of allocated points for an individual is 10 points to prevent overestimation of risk in the high-risk groups. Validation was conducted in three large cohorts in individuals on direct-acting oral anticoagulants, including dabigatran, edoxaban, rivaroxaban, and apixaban.

Clinical Risk Prediction Tool		Points
Age, years
	65-69	2
	70-74	3
	75-79	4
	≥80	5
Creatinine Clearance/eGFR (mL/min)
	30-60	1
	<30	2
Underweight (BMI <18.5)		1
Stroke/TIA/Embolism History		1
Diabetes		1
Hypertension		1
Antiplatelet Use
	Aspirin	2
	Dual-Antiplatelet	3
Nonsteroidal Anti-inflammatory (NSAID) Use		1
Bleeding History		3
Liver Disease		2
Total Score Range: 0-10 (Maximum 10 points)